How were IsoPlexis' earnings last quarter?

IsoPlexis Co. (NASDAQ:ISO) announced its earnings results on Wednesday, November, 10th. The company reported ($10.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by $9.87. The business had revenue of $4.19 million for the quarter, compared to analysts' expectations of $3.79 million. IsoPlexis had a negative net margin of 632.41% and a negative trailing twelve-month return on equity of 127.86%.

When did IsoPlexis IPO?

IsoPlexis (ISO) raised $125 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 8,333,000 shares at a price of $14.00-$16.00 per share.

NASDAQ:ISO

IsoPlexis (ISO) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ISO Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $0.76
▼
$0.76
50-Day Range: $0.74
▼
$1.13
52-Week Range: $0.60
▼
$5.10

Volume: N/A
Average Volume: 68,375 shs
Market Capitalization: $30.28 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get IsoPlexis alerts:

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About IsoPlexis Stock (NASDAQ:ISO)

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

ISO Stock News Headlines

March 5, 2024 | uk.finance.yahoo.com

Diagnostic Industry Revelations: Comprehensive Analysis of Global Distribution Deals from 2016 to 2024 Unveiled

August 18, 2023 | msn.com

Bruker to buy cell biology company PhenomeX for $108m

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

August 17, 2023 | msn.com

Bruker Enters Functional Single-Cell Biology Research Solutions With PhenomeX Acquisition

August 17, 2023 | msn.com

PhenomeX stock rallies by 137% after buyout offer from Bruker

August 17, 2023 | finance.yahoo.com

Bruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction

August 14, 2023 | markets.businessinsider.com

PhenomeX Reports Second Quarter 2023 Financial Results and Provides Business Update

August 11, 2023 | thestreet.com

IsoPlexis Corporation

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

May 16, 2023 | marketwatch.com

10-Q: PHENOMEX INC.

May 12, 2023 | finanznachrichten.de

PhenomeX Reports First Quarter 2023 Financial Results

May 5, 2023 | marketwatch.com

Single Cell Proteomics System Market Insights, Forecast to 2029 Market Size 2023-2031 Industrial Regions by Absolute Reports | with [90 Pages]

May 3, 2023 | marketwatch.com

Single Cell Proteomics Analysis System Market Insights, Forecast to 2029 Market Size and volume sale report 2023

April 14, 2023 | marketwatch.com

Tabula Rasa HealthCare Removes Interim Tag, Names Brian Adams CEO

March 21, 2023 | finance.yahoo.com

PhenomeX Strengthens Commercial Leadership Team

February 18, 2023 | finance.yahoo.com

IsoPlexis Corporation (ISO) Stock Historical Prices & Data - Yahoo Finance

February 9, 2023 | finance.yahoo.com

IsoPlexis Corporation's (NASDAQ:ISO) recent US$6.3m market cap decline means a loss of US$65k for insiders who bought this year

February 4, 2023 | benzinga.com

SHAREHOLDER ALERT: Weiss Law Investigates IsoPlexis Corporation

January 15, 2023 | finanznachrichten.de

IsoPlexis Corporation: Berkeley Lights to Acquire IsoPlexis, Creating a Premier Functional Cell Biology Company

January 12, 2023 | benzinga.com

IsoPlexis Granted U.S. Patent Titled 'METHODS OF USING NUCLEOTIDE ANALOGUES'

January 12, 2023 | msn.com

IsoPlexis expects FY22 revenue to be below consensus

January 12, 2023 | finance.yahoo.com

IsoPlexis Reports Preliminary Full Year 2022 Revenue

January 10, 2023 | msn.com

Berkeley Lights' Preliminary 2022 Results Deficient, Analysts Say All Eyes On IsoPlexis Execution

January 5, 2023 | msn.com

Morgan Stanley Maintains Equal-Weight Rating for IsoPlexis: Here's What You Need To Know

December 23, 2022 | barrons.com

Thinking about buying stock in Mullen Automotive, Cleveland-Cliffs, CarMax, IsoPlexis, or Teva Pharmaceutical?

December 23, 2022 | markets.businessinsider.com

Analysts Conflicted on These Technology Names: Workday (WDAY) and IsoPlexis (ISO)

December 23, 2022 | benzinga.com

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating IsoPlexis Corporation Buyout

See More Headlines

Receive ISO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IsoPlexis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:ISO
CUSIP: N/A
CIK: 1615055
Web: isoplexis.com
Phone: 203-208-4111
Fax: N/A
Employees: 459
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-106,000,000.00
Net Margins: -632.41%
Pretax Margin: -632.40%
Return on Equity: -127.86%
Return on Assets: -71.41%

Debt

Debt-to-Equity Ratio: 1.12
Current Ratio: 4.06
Quick Ratio: 2.50

Sales & Book Value

Annual Sales: $16.76 million
Price / Sales: 1.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.04 per share
Price / Book: 0.73

Miscellaneous

Outstanding Shares: 39,760,000
Free Float: 37,218,000
Market Cap: $30.28 million
Optionable: Not Optionable
Beta: 1.32

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Sean Mackay (Age 40)
Co-Founder, CEO, Pres & Director
Comp: $635.55k
Mr. John R. Strahley CPA (Age 55)
Chief Financial Officer
Comp: $444.11k
Mr. Rong Fan
Co-Founder & Chairman of Scientific Advisory Board
Mr. Jon Chen
VP of Scientific Alliance Technology & Co-Founder
Mr. Anthony Catalano
Sr. VP of Operations
Mr. Rajesh T. Khakhar
VP of Fin. & Principal Accounting Officer
Ms. Jing Zhou M.D. (Age 52)
Ph.D., Chief Scientific Officer
Mr. Richard W. Rew II (Age 54)
Sr. VP, Gen. Counsel & Sec.
Ms. Verna Siu
Sr. VP of Sales Operations
Ms. Carrie Carter
Sr. VP of People Operations

Key Competitors

View All Competitors

ISO Stock Analysis - Frequently Asked Questions

How were IsoPlexis' earnings last quarter?: IsoPlexis Co. (NASDAQ:ISO) announced its earnings results on Wednesday, November, 10th. The company reported ($10.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by $9.87. The business had revenue of $4.19 million for the quarter, compared to analysts' expectations of $3.79 million. IsoPlexis had a negative net margin of 632.41% and a negative trailing twelve-month return on equity of 127.86%.
When did IsoPlexis IPO?: IsoPlexis (ISO) raised $125 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 8,333,000 shares at a price of $14.00-$16.00 per share.

This page (NASDAQ:ISO) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

IsoPlexis (ISO) Stock Price, News & Analysis

About IsoPlexis Stock (NASDAQ:ISO)

ISO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ISO Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info